Jago Grahak Jago

Edit Template

Blog

Your blog category

Union Budget 2026: Counting for Consumers, Not Just Counting Consumers

Why the Budget Must Put Consumers First Private consumption drives nearly 60% of GDP, yet consumer representatives are rarely consulted during budget preparation. India’s budget framework should prioritize consumer welfare as the foundation of economic growth. Taxation Concerns Income tax structures fail to account for inflation, effectively penalizing wage earners. A modest annual increment often pushes them into a higher tax bracket, even though their real income has barely grown. Recommendations include indexing tax slabs to inflation and simplifying compliance requirements. Affordability Issues Rising costs in food, fuel, healthcare, and education strain household budgets disproportionately. Growth is meaningless if families feel squeezed at the kitchen table. GST rationalization on essentials and robust price monitoring mechanisms are needed. Housing Crisis Affordable housing momentum has stalled, leaving first-time buyers stranded. Enhanced loan deductions and buyer protections against unfair practices are essential, framing homes as necessities rather than speculative assets. Gig Economy Workers Millions working in informal sectors lack social security coverage. Flexibility should not mean fragility. Health insurance, accident cover, and pensions must extend to gig workers with uniform minimum wage structures. Rural Consumers Rural demand anchors India’s consumption patterns, yet rural populations are treated as passive beneficiaries rather than active stakeholders. Dedicated 24/7 consumer helplines, fair agricultural pricing, and affordable credit access are needed. Market Regulation Hidden charges and poor grievance redressal across telecom, aviation, insurance, and healthcare sectors undermine consumer trust. Strengthened regulatory frameworks and deterrent penalties for unfair practices are essential. The Union Budget is a social contract. A consumer-focused approach ensures fairness and affordability while recognizing that sustained economic growth depends on household confidence and purchasing power.

Union Budget 2026: Counting for Consumers, Not Just Counting Consumers Read More »

Are Baby Foods Safe and Good for Your Baby’s Health?

A USD 9.9 Billion Market Under Scrutiny The Indian baby food market, valued at USD 9.9 billion in 2025, is projected to reach USD 13.4 billion by 2030. Despite marketing claims of safety and nutrition, significant concerns exist regarding hidden dangers in these products. Five Main Baby Food Categories Infant Milk Substitutes (IMS): Products marketed as alternatives when breastfeeding isn’t possible Complementary Foods: Packaged cereals designed to supplement breastmilk after six months Ready-to-Eat Meals: Pre-prepared foods in pouches, jars, or cups Baby/Toddler Snacks: Finger foods like puffs, melts, crackers, and teething biscuits Toddler Nutrition Drinks: Packaged beverages claiming to support growth and immunity The Sugar Problem According to WHO guidelines, children aged 6-23 months should avoid foods high in sugar. The ICMR-NIN Dietary Guideline (2024) states: “No added sugar for children under 2 years old.” However, research found approximately 41% of commercially available baby food brands contain high sugar levels. Excess early sugar consumption correlates with increased risk of type 2 diabetes and hypertension later in life. The Nestle Cerelac Controversy A 2024 investigation revealed a stark double standard: all 15 Cerelac products sold in India contained added sugar (approximately 3 grams per serving), while identical products in European markets like the UK and Germany contained almost no added sugar. Heavy Metal Contamination Heavy metals like lead, arsenic, cadmium, and mercury accumulate in baby foods, particularly rice-based cereals. A 2021 U.S. Congressional report documented dangerous contamination levels. Estimates suggest 95% of tested baby foods contain detectable heavy metal levels. Recommendations for Parents Examine labels carefully for added sugars, honey, or “natural” claims Prioritize freshly prepared homemade foods Avoid rice-based cereals; substitute oats or millets Support regulatory reform campaigns Policy Recommendations Ban added sugars in infant foods per WHO guidelines Establish stringent heavy metal limits Mandate clear disclosure of sugars, contaminants, and sourcing Launch consumer awareness campaigns – JAGO GRAHAK JAGO

Are Baby Foods Safe and Good for Your Baby’s Health? Read More »

Food Adulteration in India: Poison in Every Plate

A Silent Crisis on Every Indian Table Millions of Indians consume milk, cereal, and tea daily as a ritual of nourishment and trust. Yet food meant to sustain the nation is increasingly being weaponized by greed. From fake paneer made with sulphuric acid to festive sweets containing carcinogenic dyes, food adulteration is a systemic public health crisis violating Article 21 rights. WHO statistics show 600 million annual foodborne illness cases globally with 420,000 deaths. The Scale of a Shadow Industry During 2024-25, over 170,000 food samples tested by authorities showed nearly one-third of samples in several states were non-compliant. Modern adulteration has evolved beyond simple water dilution, becoming a multi-billion-dollar shadow industry involving synthetic milk, mislabeled palm oil, and neurotoxic brighteners on vegetables. A Poison for Every Season Festive periods see fake dairy products surge during Diwali, Holi, and Eid Summer months bring synthetic colors and contaminated beverages causing typhoid and hepatitis Monsoon season involves antibiotics and formaldehyde extending shelf-life artificially Daily consumption includes turmeric laced with lead chromate and honey mixed with sugar syrup Why the System Stutters: The Enforcement Gap Three critical failures undermine the Food Safety and Standards Act of 2006: Resource shortage: Food safety receives roughly 0.02% of the health budget, leaving many districts with just one Food Safety Officer Weak penalties: Fines function as business costs rather than deterrents; license cancellations remain rare Unorganized sector gaps: Millions of micro-entrepreneurs operate outside regulatory reach The 2026 Reforms: A Double-Edged Sword Recent government initiatives introduced Perpetual Validity for licenses, eliminating renewal reviews. Simultaneously, the Risk-Based Inspection System prioritizes high-risk categories like dairy and infant food for frequent audits while reducing scrutiny of lower-risk businesses. Technology: The Final Frontier Food Safety on Wheels: Over 350 mobile testing labs operate across India, though the author advocates for 7,323 units nationally Digital traceability: QR-code systems for high-risk items like oils and honey DART initiative: Consumer-accessible rapid testing kits enabling household detection of adulterants The Path Forward: A Multi-Pronged Strategy Indexing fines to company turnover with imprisonment for hazardous substance use Tripling Food Safety Officers and upgrading laboratories Incentivizing compliance through certification programs Empowering consumers as food auditors through label checking and FSSAI utilization Food adulteration operates as a silent killer with long-term health consequences including renal failure and cancer. Safe food must be recognized and enforced as a non-negotiable fundamental right.

Food Adulteration in India: Poison in Every Plate Read More »

Palm Oil: The Invisible Ingredient in India’s Snack Revolution

The Hidden Fat in Your Favourite Snacks Palm oil has become ubiquitous in India’s processed food industry, often disguised under vague labeling like “vegetable oil” or “blended edible oil.” This ingredient has fundamentally altered food manufacturing economics while raising significant health and environmental concerns. Why Manufacturers Prefer Palm Oil Manufacturers favor palm oil for three primary reasons: cost efficiency, extended shelf life, and desirable texture properties. Its high oxidative stability means products stay fresh longer, while it simultaneously helps maintain profit margins through affordability. Indonesia and Malaysia supply India’s imports at competitive prices. Health Implications Palm oil contains approximately 50% saturated fat, primarily palmitic acid, linked to elevated LDL cholesterol. The genuine danger emerges with repeatedly heated oil, which generates trans fats and aldehydes causing inflammation and cardiovascular harm. Small-scale Indian snack manufacturers frequently reuse frying oil, magnifying these risks substantially. Common Product Applications Chips, namkeen, instant noodles, and biscuits all rely heavily on palm oil. It serves as the frying medium, provides texture in pre-fried noodle blocks, and replaces costlier ingredients like butter in biscuits. Each product delivers several grams of palm oil-derived fat, contributing to obesity and heart disease prevalence. Environmental Concerns Palm oil cultivation has driven deforestation across Indonesia and Malaysia, destroying habitats for endangered species including orangutans and Sumatran tigers. Less than one-fifth of India’s imports meet sustainable certification standards (RSPO). How to Spot Palm Oil on Labels Palm oil / Palmolein Hydrogenated vegetable fat Vegetable oil blend Palm kernel oil Edible vegetable oil (unspecified) While palm oil enables affordable food for millions, it simultaneously contributes to lifestyle diseases and environmental degradation. The challenge involves wise usage, strict regulation, and consumer education rather than outright prohibition.

Palm Oil: The Invisible Ingredient in India’s Snack Revolution Read More »

Regulators on Trial: Are Regulators in India Living Up to the Expectations of the Consumers?

When Systems Fail the People They Serve India has established multiple regulatory bodies – the RBI for banking, IRDAI for insurance, RERA for real estate, CCPA for consumer affairs, TRAI for telecom, FSSAI for food safety, CDSCO for pharmaceuticals, and DGCA for aviation. However, complaint volumes tell a different story. The National Consumer Helpline received over 83,000 complaints in 2022-23, approximately 102,000 in 2023-24, and more than 107,000 in the first quarter of 2024-25. Success Cases: When Regulations Function Real Estate: In Gurugram’s Chintels Paradiso project, Haryana RERA ordered developers to refund over Rs 1.7 crore including 11% annual interest plus compensation. Digital Lending: RBI’s guidelines forced hundreds of lending applications to either register properly or cease operations, with proposed legislation criminalizing unregulated lending with imprisonment up to seven years. The Implementation Gap Real Estate Delays: Only 20% of group housing projects in Noida have cleared financial obligations; major developers like Unitech and Amrapali collectively owe tens of thousands of crores. Insurance Mis-selling: Investment products marketed as “guaranteed” deposits, complex ULIPs sold to elderly customers requiring basic protection. Banking Problems: Consumers encounter obscure fees, unilateral contract modifications, and aggressive collection practices despite RBI oversight. Structural Limitations Systemic Stability Priority: Regulators prioritize institutional solvency over individual consumer protection Resource Constraints: Rapidly expanding caseloads exceed processing capacity Institutional Fragmentation: Digital fraud victims may navigate multiple entities without clear accountability Information Asymmetry: Contracts contain dense jargon with minimal plain-language guidance Recommendations Expedited resolution processes with cross-regulator task forces Meaningful deterrence through license revocation and public-capital-raising prohibitions Data-driven proactive supervision using real-time analytics Accessible Consumer Rights Charters at every bank and insurance counter Structured consumer participation through formal consumer councils India requires regulator mindset transformation, not institutional expansion. Success measurement should shift from institutional balance-sheet protection to human-life-savings safeguarding.

Regulators on Trial: Are Regulators in India Living Up to the Expectations of the Consumers? Read More »

Product Labels: What They Reveal – And What They Don’t

The Art of Showing Just Enough While Hiding the Rest Product labels serve as the initial connection between consumers and purchased items. Beyond decoration, they enable brand recognition while helping consumers distinguish between quality products and substandard ones. However, labels frequently conceal rather than reveal information. “If labels told the whole truth, 80-90% Marketing Managers might be out of their job.” What Labels Should Provide Product name and manufacturer identity Complete ingredient lists and nutritional information Usage instructions and expiration dates Health and safety warnings QR codes for additional product information Batch/lot numbers for production history tracing Questionable Marketing Terms “Natural” – Lacks standardized definition in many countries including India. Products may contain artificial additives or preservatives. “Organic” – Requires certification demanding 95% or higher organic ingredient content from bodies like USDA Organic or India Organic. “Sugar-Free” – Products may still contain sugar alcohols or artificial sweeteners. Regulations allow less than 0.5 grams per serving. “Clinically Proven” – A marketing term lacking uniform definition. Companies may conduct small-scale or biased studies. Indian Examples of Misleading Labels Patanjali’s Putrajeevak Beej: Marketing claims of infertility treatment sparked legal scrutiny Nestle’s Maggi Noodles: 2015 FSSAI controversy revealed excessive lead despite “No added MSG” labeling Cadbury’s Bournvita: High sugar and artificial colorants despite health benefit claims A2 Milk and Ghee: Premium-priced products lacked scientific evidence; FSSAI banned A2 labeling without proven benefits Global Examples Barilla Pasta: “Italy’s #1 Brand” when U.S. facilities produced most American-sold products H&M Greenwashing: Marketed conventional cotton as organic without substantiation Low-Fat Foods: High sugar compensation makes these deceptively unhealthy India’s Supreme Court recently mandated states establish advertising monitoring cells to combat misleading advertisements. Consumers must read beyond marketing claims to verify actual product composition.

Product Labels: What They Reveal – And What They Don’t Read More »

Playtime or Poison? Harmful & toxic toys in Indian markets

PM Modi’s Call for Safe, Indigenous Toys At the India Toy Fair 2021, Prime Minister Narendra Modi urged manufacturers to “make toys that are better for ecology and psychology,” stressing the need for eco-friendly materials, innovation, and self-reliance. He reminded the nation that toys are not trivial—they shape childhood imagination and national identity. In his Independence Day 2024 address, he reiterated that India must not depend on unsafe imports, calling for an Aatmanirbhar Bharat in toys. Yet, despite these warnings, India’s toy market remains dangerously unregulated. Raids, recalls, and seizures continue to expose lead-laden, chemically hazardous, and mechanically unsafe toys flooding shelves and online platforms. The Reality: Unsafe Toys Everywhere Recent enforcement actions reveal the scale of the crisis. Toys with excessive lead, phthalates, and explosion-prone batteries have been confiscated across India. Many were imported illegally, while others were domestically produced with recycled plastics and uncertified dyes. Parents, often lured by low prices, unknowingly expose children to hidden toxins. The result is a silent public health emergency: lead poisoning, hormonal disruption, and fire hazards—all wrapped in bright packaging. Raids and Recalls (2023–2025) Year Location Action Taken Hazard Identified Outcome 2023 Nhava Sheva Port (Mumbai) Customs seizure of Chinese toy consignments Lead paint, phthalates Thousands of toys destroyed; importers fined 2024 Bengaluru & Chennai Product recalls of battery-operated toys Exploding lithium cells Toys pulled from shelves; BIS issued safety alert 2024 Delhi NCR Market raids on local shops Uncertified plastic dolls, choking hazards Hundreds of toys confiscated; traders penalized 2025 Mumbai & Pune Raids on wholesale warehouses Excessive lead, toxic dyes Large consignments seized; criminal cases filed 2025 Online marketplaces Crackdown on uncertified imports No BIS certification, chemical hazards Listings removed; platforms warned of liability Why the Market Is Vulnerable India’s toy sector suffers from weak enforcement of BIS standards, consumer ignorance, and e-commerce loopholes. While BIS certification is mandatory, enforcement is patchy. Small traders bypass rules, importing toys without safety checks. Online platforms, meanwhile, are flooded with uncertified toys shipped directly from overseas sellers. Even domestic manufacturers cut corners, using recycled plastics and uncertified dyes to lower costs. The result is a market where unsafe toys are not the exception but the norm. The Consumer Cost Unsafe toys are not just a regulatory issue—they are a public health crisis. Lead poisoning can cause irreversible brain damage, phthalates disrupt hormones, and faulty batteries pose fire hazards. Children, the most vulnerable consumers, are being exposed daily to risks hidden inside brightly coloured playthings. The World Health Organization has repeatedly warned that no level of lead exposure is safe for children. Yet raids in India continue to uncover toys with lead levels far above permissible limits. Modi’s Vision vs. Market Reality Prime Minister Modi’s speeches have consistently highlighted toys as a sector where India can combine cultural heritage with modern innovation. He has called for toys that reflect India’s traditions, use eco-friendly materials, and meet global safety standards. But the reality is starkly different. The market is flooded with cheap imports that undermine both consumer trust and national pride. Domestic manufacturers, instead of rising to the challenge, often cut corners to compete on price. The gap between vision and reality is widening. What Needs to Change India must act decisively: Stricter Enforcement: Customs and state regulators must intensify raids and impose heavy penalties on violators. Consumer Awareness Campaigns: Parents must be educated to check for ISI/BIS marks and avoid suspiciously cheap imports. Industry Accountability: Domestic manufacturers must invest in safe, eco-friendly materials, aligning with Modi’s vision of an Aatmanirbhar Bharat toy industry. E-commerce Regulation: Platforms must be held liable for selling uncertified toys, with mandatory compliance checks. Call to Action India’s toy industry sits at a crossroads. On one side lies Prime Minister Modi’s vision of a self-reliant, eco-friendly sector that safeguards children. On the other lies the grim reality of toxic imports and unsafe domestic products flooding the market. The choice is stark: either India enforces its standards and protects its youngest citizens, or it risks turning playtime into a silent health hazard. For consumers, vigilance is the first line of defence. For regulators, decisive enforcement is overdue. A good toy should spark imagination—not endanger life. India must act now to ensure that every toy in a child’s hand is safe, sustainable, and proudly made to protect the future. 5 Things Parents Must Check Before Buying a Toy 1. Look for the BIS/ISI Mark Always check if the toy carries the Bureau of Indian Standards (BIS) certification. This mark ensures the toy has passed safety tests for chemicals, choking hazards, and mechanical risks. 2. Avoid Suspiciously Cheap Imports If the price seems too good to be true, it probably is. Ultra-cheap toys often bypass safety standards and may contain toxic paints, recycled plastics, or faulty batteries. 3. Check Labels and Packaging Read the packaging carefully. Safe toys should list the manufacturer’s details, age-appropriateness, and safety warnings. Avoid toys with missing or vague labels. 4. Be Wary of Online Marketplaces Many uncertified toys slip through e-commerce platforms. Buy only from trusted sellers and check product reviews. If the toy lacks BIS certification, don’t add it to your cart. 5. Inspect Before Play Before handing a toy to your child, inspect it for sharp edges, loose parts, or strong chemical smells. If it looks flimsy or smells of chemicals, it’s not safe.

Playtime or Poison? Harmful & toxic toys in Indian markets Read More »

India waives clinical trial requirement for drugs approved in developed markets

August 08,2024 New Delhi: The government has done away with the requirement of clinical investigation for new drugs having significant therapeutic advance over the current standard care and have already got the regulatory approval in the US, UK, Japan, Australia, Canada or the European Union. Clinical trial waivers will also be considered for new drugs for rare diseases, drugs used in pandemic situations or for special defence purposes, and gene and cellular therapy products that are approved in these developed markets, the Central Drugs Standard Control Organisation (CDSCO) said in a circular on Wednesday. The decision is aimed at speeding up the availability of new drugs and medical devices in the country. As reported by ET last week, India had previously given such waivers only for drugs and medical devices that have got regulatory clearance in the US, UK, Australia, Canada and Japan. Now the local drug regulator added the EU also to the list, people in the know told ET. Addition of the EU for the clinical trial waiver has been under consideration since 2018 when, during a meeting of the India-EU sub-commission on trade, EU officials raised the issue. After this, a proposal to include the EU for medical devices was sent to the health ministry. However, it was referred back to the CDSCO for critical review in the context of updated rules and recent notifications. The ministry also asked for deliberations in consultation with the Drug Technical Advisory Board for a fresh proposal. Rajiv Nath, forum coordinator of the Association of Indian Medical Devices Industry, told ET earlier that if India needed to give EU-based manufacturers any waiver or fast-track regulatory approval, then the country should negotiate its trade agreement with the EU on a reciprocal basis rather than simply conceding and amending its Medical Devices Rules. Source: Healthworld

India waives clinical trial requirement for drugs approved in developed markets Read More »

Wegovy, Ozempic linked with sight-threatening eye disorder in study

July 04,2024 London: Patients using Novo Nordisk’s wildly popular weigh-loss drug Wegovy and its similar medicines for type 2 diabetes may be at increased risk for a sight-threatening eye condition, according to data from a study published on Wednesday. Wegovy and Novo’s diabetes drugs Ozempic and Rybelsus all contain the same active ingredient, semaglutide, and belong to a class of medications known as GLP1 receptor agonists. The rate of the eye problem known as nonarteritic anterior ischemic optic neuropathy, or NAION, was 8.9% for those taking semaglutide for type 2 diabetes, compared with 1.8% for patients taking non-GLP-1 diabetes medications, researchers reported in JAMA Ophthalmology. Among those prescribed semaglutide for overweight or obesity, the rate of the eye condition was 6.7%, versus 0.8% for those receiving other types of medications for weight reduction. The 36-month observational study involved 710 adults with type 2 diabetes and 979 taking medications for weight loss. NAION develops from insufficient blood flow to the optic nerve and causes sudden painless vision loss in one eye. It is the second most common cause of blindness due to optic nerve damage, after glaucoma. After taking patients’ other risk factors for the condition into account, such as high blood pressure and obstructive sleep apnea, use of semaglutide was associated with a more than four times higher risk of NAION in those receiving it for diabetes and a more than seven times higher risk in patients taking it for obesity. Novo Nordisk in an emailed statement noted several limitations of the study design, which was not a randomized controlled trial. “Overall, the data published in the study is not sufficient to establish a causal association between GLP-1 receptor agonist use and NAION,” the Danish drugmaker said, adding that the condition “is not an adverse drug reaction for the marketed formulations of semaglutide.” NAION more often affects older individuals. In the overall U.S. population, the estimated annual incidence is 0.54 per 100,000 people, rising to 2.3 to 10.2 per 100,000 in adults above age 50, according to the American Academy of Ophthalmology. The prognosis for visual recovery is better for younger patients, the AAO says. Mean ages in the study were 46 among patients using semaglutide for obesity and 57 among those using it for diabetes. “This work has been carried out to a high level of quality and… does suggest an association between semaglutide treatment and one form of sight-threatening optic neuropathy, but this would ideally be tested in larger studies,” Graham McGeown of Queen’s University Belfast, who studies diabetic eye disease but was not involved in the new research, said in a statement. “Given the rapid increase in semaglutide use and its possible licensing for a range of problems other than obesity and type-2 diabetes, this issue deserves further study, but possible drug side effects always need to be balanced against likely benefits,” McGeown said. The researchers involved in the study were not immediately available to comment on their findings. Source: Healthworld

Wegovy, Ozempic linked with sight-threatening eye disorder in study Read More »